Premarket Movers | Sarepta Therapeutics Soars 44%; Celestica Jumps 12%; Cadence Design Rises over 7%; VeriSign Drops Nearly 7%

In a major win for Sarepta Therapeutics, US regulators are recommending that patients who can walk be allowed to take its gene therapy Elevidys again. The shares soared 44% in premarket trading.

Celestica raised its full-year revenue forecast for the third time in a row as demand grows for its cloud-computing segment. The shares jumped over 12% in premarket trading.

Cadence Design raised its annual sales and profit forecast, after the U.S. lifted export curbs on chip design software to China earlier this month, allowing the company to resume sales to the key market. Shares of the company rose 7.5% in overnight trading.

Cannabis company Tilray missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 2.3% year on year to $224.5 million. Its GAAP loss of $1.30 per share was significantly below analysts’ consensus estimates. The shares dropped 8.5% in premarket trading.

Berkshire Hathaway will sell about one-third of its more than $4 billion stake in VeriSign, an internet infrastructure and domain name registry company that Warren Buffett's conglomerate has invested in since 2012, VeriSign said. VeriSign fell 6.5% in premarket trading.

Nucor posted a fall in second-quarter profit, as rising raw material costs pressured the company’s steelmaking segment, sending its shares down 5.7% in premarket trading.

Whirlpool slashed its 2025 profit outlook, saying that the boost it expects from making the majority of its appliances in the US has yet to materialize as foreign rivals rushed imports into the country during the second quarter to avoid higher tariffs. Whirlpool shares fell 14% in premarket trading.